FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021130630> ?p ?o ?g. }

• W2021130630 endingPage "4262" @default.
• W2021130630 startingPage "4256" @default.
• W2021130630 abstract "Abstract The best conditioning regimen before allogeneic transplantation for high-risk diffuse large B-cell lymphoma (DLBCL) remains to be clarified. We analyzed data from 396 recipients of allotransplants for DLBCL receiving myeloablative (MAC; n = 165), reduced intensity (RIC; n = 143), or nonmyeloablative conditioning (NMAC; n = 88) regimens. Acute and chronic GVHD rates were similar across the groups. Five-year nonrelapse mortality (NRM) was higher in MAC than RIC and NMAC (56% vs 47% vs 36%; P = .007). Five-year relapse/progression was lower in MAC than in RIC/NMAC (26% vs 38% vs 40%; P = .031). Five-year progression-free survival (15%-25%) and overall survival (18%-26%) did not differ significantly between the cohorts. In multivariate analysis, NMAC and more recent transplant year were associated with lower NRM, whereas a lower Karnofsky performance score (< 90), prior relapse resistant to therapy, and use of unrelated donors were associated with higher NRM. NMAC transplants, no prior use of rituximab, and prior relapse resistant to therapy were associated with a greater risk of relapse/progression. In conclusion, allotransplantation with RIC or NMAC induces long-term progression-free survival in selected DLBCL patients with a lower risk of NRM but with higher risk of lymphoma progression or relapse." @default.
• W2021130630 created "2016-06-24" @default.
• W2021130630 creator A5001697191 @default.
• W2021130630 creator A5004234559 @default.
• W2021130630 creator A5005159945 @default.
• W2021130630 creator A5008575399 @default.
• W2021130630 creator A5011386306 @default.
• W2021130630 creator A5022864146 @default.
• W2021130630 creator A5031370568 @default.
• W2021130630 creator A5034779401 @default.
• W2021130630 creator A5042915360 @default.
• W2021130630 creator A5042974681 @default.
• W2021130630 creator A5047415265 @default.
• W2021130630 creator A5053410437 @default.
• W2021130630 creator A5056983267 @default.
• W2021130630 creator A5069393942 @default.
• W2021130630 creator A5070043884 @default.
• W2021130630 creator A5070553243 @default.
• W2021130630 creator A5071201232 @default.
• W2021130630 creator A5077959964 @default.
• W2021130630 creator A5080373697 @default.
• W2021130630 creator A5082092102 @default.
• W2021130630 creator A5082945503 @default.
• W2021130630 creator A5088486180 @default.
• W2021130630 creator A5089619585 @default.
• W2021130630 creator A5089893290 @default.
• W2021130630 date "2012-11-15" @default.
• W2021130630 modified "2023-09-30" @default.
• W2021130630 title "Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?" @default.
• W2021130630 cites W1966136277 @default.
• W2021130630 cites W1977824829 @default.
• W2021130630 cites W1983486168 @default.
• W2021130630 cites W1986483184 @default.
• W2021130630 cites W1997353354 @default.
• W2021130630 cites W2005499564 @default.
• W2021130630 cites W2038880599 @default.
• W2021130630 cites W2053278212 @default.
• W2021130630 cites W2058015212 @default.
• W2021130630 cites W2058887761 @default.
• W2021130630 cites W2064714453 @default.
• W2021130630 cites W2072854641 @default.
• W2021130630 cites W2075606933 @default.
• W2021130630 cites W2078782557 @default.
• W2021130630 cites W2085459287 @default.
• W2021130630 cites W2087378865 @default.
• W2021130630 cites W2121824293 @default.
• W2021130630 cites W2133201432 @default.
• W2021130630 cites W2140253250 @default.
• W2021130630 cites W2145304413 @default.
• W2021130630 cites W2152197116 @default.
• W2021130630 cites W2153859516 @default.
• W2021130630 cites W2155313625 @default.
• W2021130630 cites W2156056890 @default.
• W2021130630 cites W2165885469 @default.
• W2021130630 cites W2327695677 @default.
• W2021130630 cites W2618073389 @default.
• W2021130630 doi "https://doi.org/10.1182/blood-2012-06-436725" @default.
• W2021130630 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3501720" @default.
• W2021130630 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23007405" @default.
• W2021130630 hasPublicationYear "2012" @default.
• W2021130630 type Work @default.
• W2021130630 sameAs 2021130630 @default.
• W2021130630 citedByCount "115" @default.
• W2021130630 countsByYear W20211306302012 @default.
• W2021130630 countsByYear W20211306302013 @default.
• W2021130630 countsByYear W20211306302014 @default.
• W2021130630 countsByYear W20211306302015 @default.
• W2021130630 countsByYear W20211306302016 @default.
• W2021130630 countsByYear W20211306302017 @default.
• W2021130630 countsByYear W20211306302018 @default.
• W2021130630 countsByYear W20211306302019 @default.
• W2021130630 countsByYear W20211306302020 @default.
• W2021130630 countsByYear W20211306302021 @default.
• W2021130630 countsByYear W20211306302022 @default.
• W2021130630 countsByYear W20211306302023 @default.
• W2021130630 crossrefType "journal-article" @default.
• W2021130630 hasAuthorship W2021130630A5001697191 @default.
• W2021130630 hasAuthorship W2021130630A5004234559 @default.
• W2021130630 hasAuthorship W2021130630A5005159945 @default.
• W2021130630 hasAuthorship W2021130630A5008575399 @default.
• W2021130630 hasAuthorship W2021130630A5011386306 @default.
• W2021130630 hasAuthorship W2021130630A5022864146 @default.
• W2021130630 hasAuthorship W2021130630A5031370568 @default.
• W2021130630 hasAuthorship W2021130630A5034779401 @default.
• W2021130630 hasAuthorship W2021130630A5042915360 @default.
• W2021130630 hasAuthorship W2021130630A5042974681 @default.
• W2021130630 hasAuthorship W2021130630A5047415265 @default.
• W2021130630 hasAuthorship W2021130630A5053410437 @default.
• W2021130630 hasAuthorship W2021130630A5056983267 @default.
• W2021130630 hasAuthorship W2021130630A5069393942 @default.
• W2021130630 hasAuthorship W2021130630A5070043884 @default.
• W2021130630 hasAuthorship W2021130630A5070553243 @default.
• W2021130630 hasAuthorship W2021130630A5071201232 @default.
• W2021130630 hasAuthorship W2021130630A5077959964 @default.
• W2021130630 hasAuthorship W2021130630A5080373697 @default.
• W2021130630 hasAuthorship W2021130630A5082092102 @default.
• W2021130630 hasAuthorship W2021130630A5082945503 @default.
• W2021130630 hasAuthorship W2021130630A5088486180 @default.

• next